Patients with high-burden rosacea have a longer and more costly skin care regimen, greater disease severity, and are often younger at onset of first symptoms compared with those who have less severe rosacea. This is according to a study in the Journal of Dermatology Treatment.
Individuals from the United States, Canada, Germany, France, Italy, and the United Kingdom were invited to participate in a self-administered online survey (n=710; mean age, 44.5±13.8 years). Participants were between 18 and 70 years of age and reported having clinically confirmed rosacea within the previous 2 years. The participants were also required to have taken a treatment prescribed for their rosacea within the past 12 months. The impact of rosacea on quality of life, lifestyle adaptation, time trade-off, and willingness to pay were measured. The high-burden population was defined as those whose ratings were greater than the median of all participants. Several factors and characteristics were examined to identify elements associated with high-burden disease.
A total of 158 patients scored positive for ≥3 of the 4 high-burden domains and were considered participants with high-burden rosacea. Patients with high-burden rosacea were more likely to spend a greater amount of time on daily skin care (P <.01) and reported twice the amount of impact of disease on work productivity in the past week (31.3% vs 3.8%; P <.01).
Based on a single-question score of 0 to 10, the impact of rosacea on quality of life was higher in participants with high-burden rosacea vs the rest of the cohort (7.5±1.5 vs 4.3±2.4, respectively; P <.01). Patients with high-burden rosacea were also more likely to report ≥1 visit to the emergency department in the previous 12 months (41.8% vs 11.2%; P <.01).
Characteristics associated with high-burden disease in the multivariate risk analysis included being ≤30 years of age at first symptoms (odds ratio [OR], 2.83), higher self-reported rosacea severity (OR, 2.65), costly skin care routine (OR, 2.30), oily skin type (OR, 1.98), and seeing a physician within 1 to 3 months vs ≥12 months after first symptoms (OR, 2.36).
Limitations of the study included the use of a survey questionnaire to gather data as well as the self-reported nature of those data.
The researchers suggest that clinicians should use burden-related questions “in everyday practice to ensure treatment is aligned with patients’ disease experience and to maximize the opportunity of reducing an individual’s burden of rosacea.”
The authors disclosed financial interests with Galderma, which funded the survey, as well as Allergan, Bayer, Cipher, and Valeant.
Tan J, Steinhoff M, Bewley A, Gieler U, Rives V. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey [published online June 18, 2019]. J Dermatolog Treat. doi:10.1080/09546634.2019.1623368.